1. ALLA AKTIER
  2. NYHETER
  3. ASARINA PHARMA

Asarina Pharma

Nyheter Asarina Pharma Nyheter alla bolag

Asarina Pharma AB announces new date for the release of Annual Report for 2023

MARKN.

Asarina Pharma AB (publ) (”the Company”) announces today that the Board has decided to postpone the release of the Annual Report for 2023 to June 4th, 2024.

The release is postponed as the Company is still working with its auditors to resolve the last outstanding points in the Annual Report.
For additional information, please contact:
Jakob Dynnes Hansen, CFO, Asarina Pharma AB
Telefon: +45 5132 3698
E-post: jakob.dynnes@asarinapharma.com

The Company’s Certified Adviser is Carnegie Investment Bank AB (publ).

For further information, please contact:
Peter Nordkild, CEO, Asarina Pharma AB
Phone: +45 25 47 16 46
E-mail: peter.nordkild@asarinapharma.com

Jakob Dynnes Hansen, CFO, Asarina Pharma AB
Tel: +45 5132 3698
E-mail: jakob.dynnes@asarinapharma.com

The Company’s Certified Adviser is Carnegie Investment Bank AB (publ)

About Asarina Pharma
Asarina Pharma is a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive Compulsive Disorder that still lack safe, efficacious pharmaceutical treatments.

Attachments
Asarina Pharma AB announces new date for the release of Annual Report for 2023

Datum 2024-05-28, kl 22:00
Källa MFN
Bifogade filer
Asarina Pharma AB announces new date for the release of Annual Report for 2023
Affiliate
200 kr till alla nya kunder! Just nu får alla nya kunder på Nordnet 200 kronor insatta i fonden Nordnet One Offensiv. Erbjudandet gäller mellan 1:e och 30:e september!
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet